BiomX

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CPhI India 2021

Participation Not Confirmed

Update your events

BiomX Presents Preclinical Data of Phage Targeting Klebsiella Pneumoniae for Primary Sclerosing Cholangitis and Inflammatory Bowel Disease

Lead Product(s): BX003

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BX003

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 16, 2020

Details:

Presentation featured at The Liver Meeting® 2020, the AASLD Annual Meeting, details support for the design of phage therapy candidate BX003, an orally delivered candidate phage therapy targeting Klebsiella pneumoniae for the treatment of both IBD and PSC.

BiomX

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CPhI India 2021

Participation Not Confirmed

Update your events

BiomX Announces Dosing of First Subject in Phase 1a Study of BX002 Phage Therapy for Inflammatory Bowel Disease

Lead Product(s): BX002

Therapeutic Area: Gastroenterology Product Name: BX002

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 03, 2020

Details:

The first-in-human study is designed to evaluate the safety, pharmacokinetics, and ability of orally-administered BX002 to deliver viable phage to the gut.

BiomX

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CPhI India 2021

Participation Not Confirmed

Update your events

BiomX Presents Preclinical Data on Phage Targeting Multidrug Resistant Klebsiella pneumoniae Bacteria at the IDSA IDWeek Conference 2020

Lead Product(s): BX002

Therapeutic Area: Gastroenterology Product Name: BX002

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 21, 2020

Details:

The poster presentation details a phage therapy panel, comprised of phage directed against Klebsiella pneumoniae, showing a broad target host range and the potential to address carbapenem-resistant and extended spectrum beta-lactamase (ESBL)-producing bacteria.